A systematic review examining the relationship between cytokines and cachexia in incurable cancer

D Robert Paval, Rebekah Patton, James McDonald, Richard J E Skipworth, Iain J Gallagher, Barry J Laird, Caledonian Cachexia Collaborative, D Robert Paval, Rebekah Patton, James McDonald, Richard J E Skipworth, Iain J Gallagher, Barry J Laird, Caledonian Cachexia Collaborative

Abstract

Cancer cachexia is an unmet clinical need that affects more than 50% of patients with cancer. The systemic inflammatory response, which is mediated by a network of cytokines, has an established role in the genesis and maintenance of cancer as well as in cachexia; yet, the specific role of the cytokine milieu in cachexia requires elucidation. This systematic review aims to examine the relationship between cytokines and the cachexia syndrome in patients with incurable cancer. The databases MEDLINE, EMBASE, CINAHL, CENTRAL, PsycINFO, and Web of Science were searched for studies published between 01/01/2004 and 06/01/2020. Included studies measured cytokines and their relationship with cachexia and related symptoms/signs in adults with incurable cancer. After title screening (n = 5202), the abstracts (n = 1264) and the full-text studies (n = 322) were reviewed independently by two authors. The quality assessment of the selected papers was conducted using the modified Downs and Black checklist. Overall, 1277 patients with incurable cancer and 155 healthy controls were analysed in the 17 eligible studies. The mean age of the patients was 64 ± 15 (mean ± standard deviation). Only 34% of included participants were female. The included studies were assessed as moderate-quality to high-quality evidence (mean quality score: 7.8; range: 5-10). A total of 31 cytokines were examined in this review, of which interleukin-6 (IL-6, 14 studies) and tumour necrosis factor-α (TNF-α, 12 studies) were the most common. The definitions of cachexia and the weight-loss thresholds were highly variable across studies. Although the data could not be meta-analysed due to the high degree of methodological heterogeneity, the findings were discussed in a systematic manner. IL-6, TNF-α, and IL-8 were greater in cachectic patients compared with healthy individuals. Also, IL-6 levels were higher in cachectic participants as opposed to non-cachectic patients. Leptin, interferon-γ, IL-1β, IL-10, adiponectin, and ghrelin did not demonstrate any significant difference between groups when individuals with cancer cachexia were compared against non-cachectic patients or healthy participants. These findings suggest that a network of cytokines, commonly IL-6, TNF-α, and IL-8, are associated with the development of cachexia. Yet, this relationship is not proven to be causative and future studies should opt for longitudinal designs with consistent methodological approaches, as well as adequate techniques for analysing and reporting the results.

Trial registration: ClinicalTrials.gov NCT04406662.

Keywords: Cachexia; Cancer; Cytokines; Weight loss.

Conflict of interest statement

None declared.

© 2022 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of Society on Sarcopenia, Cachexia and Wasting Disorders.

Figures

Figure 1
Figure 1
Flow diagram of the study selection protocol.

References

    1. Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 2011;12:489–495.
    1. Argilés JM, Busquets S, Stemmler B, López‐Soriano FJ. Cancer cachexia: understanding the molecular basis. Nat Rev Cancer 2014;14:754–762.
    1. Ross PJ, Ashley S, Norton A, Priest K, Waters JS, Eisen T, et al. Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers? Br J Cancer 2004;90:1905–1911.
    1. Takayama K, Atagi S, Imamura F, Tanaka H, Minato K, Harada T, et al. Quality of life and survival survey of cancer cachexia in advanced non‐small cell lung cancer patients—Japan nutrition and QOL survey in patients with advanced non‐small cell lung cancer study. Support Care Cancer 2016;24:3473–3480.
    1. Aoyagi T, Terracina KP, Raza A, Matsubara H, Takabe K. Cancer cachexia, mechanism and treatment. World J Gastrointest Oncol 2015;7:17–24.
    1. Baracos VE, Martin L, Korc M, Guttridge DC, Fearon KCH. Cancer‐associated cachexia. Nat Rev Dis Primers 2018;4:171015–171022.
    1. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer‐related inflammation. Nature 2008;454:436–444.
    1. Diakos CI, Charles KA, McMillan DC, Clarke SJ. Cancer‐related inflammation and treatment effectiveness. Lancet Oncol 2014;15:e493–e503.
    1. Lippitz BE, Harris RA. Cytokine patterns in cancer patients: a review of the correlation between interleukin 6 and prognosis. OncoImmunology 2016;5:e1093722.
    1. Wang M, Zhao J, Zhang L, Wei F, Lian Y, Wu Y, et al. Role of tumor microenvironment in tumorigenesis. J Cancer 2017;8:761–773.
    1. Landskron G, De La Fuente M, Thuwajit P, Thuwajit C, Hermoso MA. Chronic inflammation and cytokines in the tumor microenvironment. J Immunol Res 2014;2014:149185–149194.
    1. Fearon KCH, Glass DJ, Guttridge DC. Cancer cachexia: mediators, signaling, and metabolic pathways. Cell Metab Elsevier 2012;16:153–166.
    1. Lippitz BE. Cytokine patterns in patients with cancer: a systematic review. Lancet Oncol 2013;14:e218–e228.
    1. Gunawardene A, Dennett E, Larsen P. Prognostic value of multiple cytokine analysis in colorectal cancer: a systematic review. J Gastrointest Oncol 2019;10:e3552–e3559.
    1. Matthys P, Billiau A. Cytokines and cachexia. Nutrition 1997;13:763–770.
    1. Argilés JM, Busquets S, Toledo M, López‐Soriano FJ. The role of cytokines in cancer cachexia. Curr Opin Support Palliat Care 2009;3:263–268.
    1. Vagnildhaug OM, Brunelli C, Hjermstad MJ, Strasser F, Baracos V, Wilcock A, et al. A prospective study examining cachexia predictors in patients with incurable cancer. BMC Palliat Care 2019;18:46.
    1. Trac MH, McArthur E, Jandoc R, Dixon SN, Nash DM, Hackam DG, et al. Macrolide antibiotics and the risk of ventricular arrhythmia in older adults. CMAJ 2016;188:E120–E129.
    1. Fortunati N, Manti R, Birocco N, Pugliese M, Brignardello E, Ciuffreda L, et al. Pro‐inflammatory cytokines and oxidative stress/antioxidant parameters characterize the bio‐humoral profile of early cachexia in lung cancer patients. Oncol Rep 2007;18:1521–1527.
    1. Grim‐Stieger M, Keilani M, Mader RM, Marosi C, Schmidinger M, Zielinski CC, et al. Serum levels of tumour necrosis factor‐α and interleukin‐6 and their correlation with body mass index, weight loss, appetite and survival rate—preliminary data of Viennese outpatients with metastatic cancer during palliative chemotherapy. Eur J Cancer Care 2008;17:454–462.
    1. Takahashi M, Terashima M, Takagane A, Oyama K, Fujiwara H, Wakabayashi G. Ghrelin and leptin levels in cachectic patients with cancer of the digestive organs. Int J Clin Oncol 2009;14:315–320.
    1. Gioulbasanis I, Georgoulias P, Vlachostergios PJ, Baracos V, Ghosh S, Giannousi Z, et al. Mini Nutritional Assessment (MNA) and biochemical markers of cachexia in metastatic lung cancer patients: interrelations and associations with prognosis. Lung Cancer 2011;74:516–520.
    1. Scheede‐Bergdahl C, Watt HL, Trutschnigg B, Kilgour RD, Haggarty A, Lucar E, et al. Is IL‐6 the best pro‐inflammatory biomarker of clinical outcomes of cancer cachexia? Clin Nutr 2012;31:85–88.
    1. Op den Kamp CM, Langen RC, Snepvangers FJ, De TCC, Schellekens JM, Laugs F, et al. Nuclear transcription factor κ B activation and protein turnover adaptations in skeletal muscle of patients with progressive stages of lung cancer cachexia. Am J ClinNutr 2013;98:738–748.
    1. Fujiwara Y, Kobayashi T, Chayahara N, Imamura Y, Toyoda M, Kiyota N, et al. Metabolomics evaluation of serum markers for cachexia and their intra‐day variation in patients with advanced pancreatic cancer. PLoS ONE 2014;9:e113259.
    1. Lu Z‐H, Yang L, Yu J‐W, Lu M, Li J, Zhou J, et al. Weight loss correlates with macrophage inhibitory cytokine‐1 expression and might influence outcome in patients with advanced esophageal squamous cell carcinoma. Asian Pac J Cancer Prev 2014;15:6047–6052.
    1. Bilir C, Engin H, Can M, Temi YB, Demirtas D. The prognostic role of inflammation and hormones in patients with metastatic cancer with cachexia. Med Oncol 2015;32:56–69.
    1. Srdic D, Plestina S, Sverko‐Peternac A, Nikolac N, Simundic A‐M, Samarzija M. Cancer cachexia, sarcopenia and biochemical markers in patients with advanced non‐small cell lung cancer‐chemotherapy toxicity and prognostic value. Support Care Cancer 2016;24:4495–4502.
    1. Penafuerte CA, Gagnon B, Sirois J, Murphy J, MacDonald N, Tremblay ML. Identification of neutrophil‐derived proteases and angiotensin II as biomarkers of cancer cachexia. BJC 2016;114:680–687.
    1. Lerner L, Gyuris J, Nicoletti R, Gifford J, Krieger B, Jatoi A. Growth differentiating factor‐15 (GDF‐15): a potential biomarker and therapeutic target for cancer‐associated weight loss. Oncol Lett 2016;12:4219–4223.
    1. Bye A, Wesseltoft‐Rao N, Iversen PO, Skjegstad G, Holven KB, Ulven S, et al. Alterations in inflammatory biomarkers and energy intake in cancer cachexia: a prospective study in patients with inoperable pancreatic cancer. Med Oncol 2016;33:54–68.
    1. Fogelman DR, Morris J, Xiao L, Hassan M, Vadhan S, Overman M, et al. A predictive model of inflammatory markers and patient‐reported symptoms for cachexia in newly diagnosed pancreatic cancer patients. Support Care Cancer 2017;25:1809–1817.
    1. Demiray G, Degirmencioglu S, Ugurlu E, Yaren A. Effects of serum leptin and resistin levels on cancer cachexia in patients with advanced‐stage non‐small cell lung cancer. Clin Med Insights: Oncol 2017;11:1179554917690144.
    1. Murton AJ, Maddocks M, Stephens FB, Marimuthu K, England R, Wilcock A. Consequences of late‐stage non‐small‐cell lung cancer cachexia on muscle metabolic processes. Clin Lung Cancer 2017;18:e1–e11.
    1. Hou Y‐C, Wang C‐J, Chao Y‐J, Chen H‐Y, Wang H‐C, Tung H‐L, et al. Elevated serum interleukin‐8 level correlates with cancer‐related cachexia and sarcopenia: an indicator for pancreatic cancer outcomes. J Clin Med 2018;7:502.
    1. The World Bank . World Bank country and lending groups—country classification 2020. Available from:
    1. Baumgartner RN. Body composition in healthy aging. Ann NY Acad Sci. 2000;904:437–448.
    1. Altara R, Manca M, Hermans KCM, Daskalopoulos EP, Hermans RJ, Struijker‐Boudier HA, et al. Diurnal rhythms of serum and plasma cytokine profiles in healthy elderly individuals assessed using membrane based multiplexed immunoassay. J Transl Med 2015;13:129.
    1. Nilsonne G, Lekander M, Åkerstedt T, Axelsson J, Ingre M. Diurnal variation of circulating interleukin‐6 in humans: a meta‐analysis. PLoS ONE 2016;11:e0165799.
    1. Carson JA, Baltgalvis KA. Interleukin 6 as a key regulator of muscle mass during cachexia. Exerc Sport Sci Rev 2010;38:168–176.
    1. Kumari N, Dwarakanath BS, Das A, Bhatt AN. Role of interleukin‐6 in cancer progression and therapeutic resistance. Tumor Biol 2016;37:11553–11572.
    1. White PJ. IL‐6, cancer and cachexia: metabolic dysfunction creates the perfect storm. Transl Cancer Res 2017;6:S280–S285.
    1. Bayliss TJ, Smith JT, Schuster M, Dragnev KH, Rigas JR. A humanized anti‐IL‐6 antibody (ALD518) in non‐small cell lung cancer. Expert Opin Biol Ther 2011;11:1663–1668.
    1. Ando K, Takahashi F, Motojima S, Nakashima K, Kaneko N, Hoshi K, et al. Possible role for tocilizumab, an anti‐interleukin‐6 receptor antibody, in treating cancer cachexia. J Clin Oncol 2013;31:e69–e72.
    1. Hirata H, Tetsumoto S, Kijima T, Kida H, Kumagai T, Takahashi R, et al. Favorable responses to tocilizumab in two patients with cancer‐related cachexia. J Pain Symptom Manage 2013;46:e9–e13.
    1. Ando K, Takahashi F, Kato M, Kaneko N, Doi T, Ohe Y, et al. Tocilizumab, a proposed therapy for the cachexia of Interleukin6‐expressing lung cancer. PLoS ONE 2014;9:e102436.
    1. Patsalos O, Dalton B, Himmerich H. Effects of IL‐6 signaling pathway inhibition on weight and BMI: a systematic review and meta‐analysis. Int J Mol Sci 2020;21:6290.
    1. Li H, Malhotra S, Kumar A. Nuclear factor‐kappa B signaling in skeletal muscle atrophy. J Mol Med 2008;86:1113–1126.
    1. Hayden MS, Ghosh S. Regulation of NF‐κB by TNF family cytokines. Semin Immunol 2014;26:253–266.
    1. Jatoi A, Dakhil SR, Nguyen PL, Sloan JA, Kugler JW, Rowland KM, et al. A placebo‐controlled double blind trial of etanercept for the cancer anorexia/weight loss syndrome: results from NOOC1 from the North Central Cancer Treatment Group. Cancer 2007;110:1396–1403.
    1. Wiedenmann B, Malfertheiner P, Friess H, Ritch P, Arseneau J, Mantovani G, et al. A multicenter, phase II study of infliximab plus gemcitabine in pancreatic cancer cachexia. J Support Oncol 2008;6:18–25.
    1. Wu C, Fernandez SA, Criswell T, Chidiac TA, Guttridge D, Villalona‐Calero M, et al. Disrupting cytokine signaling in pancreatic cancer: a phase I/II study of etanercept in combination with gemcitabine in patients with advanced disease. Pancreas 2013;42:813–818.
    1. Chasen M, Hirschman SZ, Bhargava R. Phase II study of the novel peptide‐nucleic acid OHR118 in the management of cancer‐related anorexia/cachexia. J Am Med Dir Assoc 2011;12:62–68.
    1. McDonald JJ, McMillan DC, Laird BJA. Targeting IL‐1α in cancer cachexia: a narrative review. Curr Opin Support Palliat Care 2018;12:453–459.
    1. Zhang D, Zheng H, Zhou Y, Tang X, Yu B, Li J. Association of IL‐1beta gene polymorphism with cachexia from locally advanced gastric cancer. BMC Cancer 2007;7:14–27.
    1. Matthys P, Dukmans R, Proost P, Van Damme J, Heremans H, Sobis H, et al. Severe cachexia in mice inoculated with interferon‐γ‐producing tumor cells. Int J Cancer 1991;49:77–82.
    1. Proctor MJ, Morrison DS, Talwar D, Balmer SM, O'Reilly DSJ, Foulis AK, et al. An inflammation‐based prognostic score (mGPS) predicts cancer survival independent of tumour site: a Glasgow Inflammation Outcome Study. Br J Cancer 2014;104:726–734.
    1. Haidich AB. Meta‐analysis in medical research. Hippokratia 2010;14:29–37.
    1. Straus S, Glasziou P, Richardson WS, Haynes BR. Evidence‐based Medicine: How to Practice and Teach EBM, Fifth ed. Edinburgh: Elsevier; 2019.
    1. von Haehling S, Morley JE, Coats AJS, Anker SD. Ethical guidelines for publishing in the Journal of Cachexia, Sarcopenia and Muscle: update 2019. J Cachexia Sarcopenia Muscle 2019;10:1143–1145.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner